Su1140 – Prevalence of Hiatal Hernia in Patients with Achalasia

Background: Esophageal squamous cell carcinoma (ESCC) is an aggressive malignant disease and esophagectomy is still the main treatment method.There were only several valuable and convenient markers for the detection or prediction of the disease progression and outcome, but low sensitivity of the markers limited the practice use.CD98 is a singletransmembrane glycoprotein, which has two main functions, the transportation of amino acids and regulation of some cell functions by binding to the cytoplasmic tail by β-integrin.CD98 had been reported to be a prognostic factor in many different cancers.However, these were only fewer reports in patients with ESCC.The aim of this study is to evaluate the expressions of CD98 in patients with ESCC and assessed their clinical relevance.Material and methods: Patients with ESCC who received esophagectomy with reconstruction between 1996 and 2011 were enrolled in this retrospective study.Those who had received preoperative chemoradiotherapy or death within 30 days after surgery were excluded.The clinicopathological information were collected.Tumor staging was classified according to the 7 th edition of AJCC cancer staging system.Expression of CD98 in paraffin embedded tumor samples were analyzed by immunohistochemistry staining and scored with a semi-quantitative method.According the expression of CD98, the patients were grouped as low and high expression subgroups.The CD98 expression, clinicopathological parameters and the survival between these two subgroups were analyzed and compared.Results: There were 142 males and 13 females with a mean age of 64.2 years (range 36-88 years).According to the assessment of the immunohistochemical staining, 107 (69.0%) patients had CD98 high expression in tumor tissue and the other 48 patients had low expression of CD98, that included 5 patients had no expression in tumor tissue.There were no significant correlations between clinicopathological parameters and the expression of CD98 except perineural invasion.The median follow-up time was 22.7 months (IQR: 10.7-67.4months).There were 96 patients with tumor recurrence or metastasis.The 3-year and 5-year disease-free survival (DFS) rate were 36.5% and 32.1%, respectively.Patients with less invasive depth, nodal free status, early pathological stage, short tumor length and no lymphovascular invasion had a better DFS, but CD98 expression did not influence the DFS (p=0.393)(Table 1).The 3-year and 5-year overall survival rate were 36.1% and 27.6%, respectively.Patients with nodal free status and early pathological stage had a better OS, but CD98 expression also did not influence the OS (p=0.210)(Table 1).Conclusions: Different with other cancers, CD98 had a high expression percentage in surgical specimens in this study, but there was not significantly associated with prognosis.